How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study

Digestive and Liver Disease

Volumn 45, Issue 9, 2013, Pages 733-737

  Bermejo, Fernando ^a   Algaba, Alicia ^a   Chaparro, María ^b,c   Taxonera, Carlos ^d   Garrido, Elena ^e   García Arata, Isabel ^a   Guerra, Iván ^a   Gisbert, Javier P ^b,c   Olivares, David ^d   de la Poza, Gema ^a   López Sanromán, Antonio ^e  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anti tumour necrosis factor; Inflammatory bowel disease; Quantiferon; Tuberculin skin test; Tuberculosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BCG VACCINATION; CHEMOPROPHYLAXIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; ENTERITIS; EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; REPEAT PROCEDURE; SCREENING TEST; SMOKING; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS; WORKPLACE;

ANTI-TUMOUR NECROSIS FACTOR; INFLAMMATORY BOWEL DISEASE; QUANTIFERON; TUBERCULIN SKIN TEST; TUBERCULOSIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882272543     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.03.005     Document Type: Article

References (49)

1. Rahier J.F., Ben-Horin S., Chowers Y. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's Colitis 2009, 3:47-91.
2. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine 2001, 345:1098-1104.
3. American Thoracic Society Targeted tuberculin testing and treatment of latent TB infection. ATS guidelines 1999, American Thoracic Society, Available at. http://www.thoracic.org/sections/publications/statements/pages/mtpi/latentTB1-27.html.
4. British Thoracic Society Standards of Care Committee BTS recommendations for assessing risk and for managing M TB infection and disease in patients due to start anti-TNF alpha treatment. Thorax 2005, 60:800-805.
5. López-San Román A., Obrador A., Fortún J., et al. Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update. Gastroenterologia y Hepatologia 2006, 29:81-84.
6. Rampton D.S. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005, 54:1360-1362.
7. Theis V.S., Rhodes J.M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2008, 27:19-30.
8. Carmona L., Gómez-Reino J.J., Rodríguez-Valverde V.al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis and Rheumatism 2005, 52:1766-1772. BIOBADASER Group.
9. Colombel J.F., Loftus E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
10. Gómez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis and Rheumatism 2003, 48:2122-2127.
11. Mow W.S., Abreu-Martin M.T., Papadakis K.A., et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clinical Gastroenterology and Hepatology 2004, 2:309-313.
12. Schoepfer A.M., Flogerzi B., Fallegger S., et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. American Journal of Gastroenterology 2008, 103:2799-2806.
13. Hatemi G., Melikoglu M., Fresko I., et al. Infliximab does not suppress the tuberculin skin test (purified protein derivative). Journal of Rheumatology 2007, 34:474-480.
14. ® TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflammatory Bowel Diseases 2011, 17:77-83.
15. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1989, 170(Suppl.):2-6.
16. Kunst H. Diagnosis of latent TB infection: the potential role of new technologies. Respiratory Medicine 2006, 100:2098-2106.
17. American Thoracic Society Targeted tuberculin testing and treatment of latent tuberculosis infection. American Journal of Respiratory and Critical Care Medicine 2000, 161:S221-S247.
18. European Centre for Disease Prevention and Control/WHO Regional Office for Europe Tuberculosis surveillance and monitoring in Europe 2012 2012, European Centre for Disease Prevention and Control, Stockholm, Available at. http://ecdc.europa.eu/en/publications/Publications/1203-Annual-TB-Report.pdf.
19. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of Internal Medicine 2008, 149:177-184.
20. Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of Internal Medicine 2007, 146:340-354.
21. Hamdi H., Mariette X., Godot V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Research and Therapy 2006, 8:R114.
22. Del Tedesco E., Roblin X., Laharie D., et al. Does anti-TNF therapy influence the performance of mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience. Inflammatory Bowel Diseases 2011, 17:1824.
23. Matulis G., Jüni P., Villiger P.M., et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Annals of the Rheumatic Diseases 2008, 67:84-90.
24. Smith R., Cattamanchi A., Steingart K.R., et al. Interferon-γ release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Current Opinion in Rheumatology 2011, 23:377-384.
25. Park J.H., Seo G.Y., Lee J.S., et al. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. Journal of Rheumatology 2009, 36:2158-2163.
26. Chen D.Y., Shen G.H., Hsieh T.Y., et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis and Rheumatism 2008, 59:800-806.
27. Fuchs I., Avnon L., Freud T., et al. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clinical Rheumatology 2009, 28:167-172.
28. Joven B.E., Almodóvar R., Galindo M., et al. Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?. Annals of the Rheumatic Diseases 2006, 65:699.
29. Denkinger C.M., Dheda K., Pai M. Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion?. Clinical Microbiology and Infection 2011, 17:806-814.
30. Pathan A.A., Wilkinson K.A., Klenerman P., et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. Journal of Immunology 2001, 167:5217-5225.
31. Papay P., Eser A., Winkler S., et al. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflammatory Bowel Diseases 2011, 17:84-90.
32. Bocchino M., Matarese A., Bellofiore B., et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. European Journal of Clinical Microbiology and Infectious Diseases 2008, 27:907-913.
33. Cobanoglu N., Ozcelik U., Kalyoncu U., et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. International Journal of Tuberculosis and Lung Disease 2007, 11:1177-1182.
34. Ponce de Leon D., Acevedo-Vasquez E., Alvizuri S., et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. Journal of Rheumatology 2008, 35:776-781.
35. Papay P., Primas C., Eser A., et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors. Alimentary Pharmacology and Therapeutics 2012, 36:858-865.
36. Ramos JM, Masiá M, Rodríguez JC, et al. Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med; in press.
37. Madhukar P., Lewinsohn D.M. Interferon gamma assays for TB: is anergy the achilles' heel?. American Journal of Respiratory and Critical Care Medicine 2005, 172:519-521.
38. Ferrara G., Losi M., Meacci M., et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of TB infection. American Journal of Respiratory and Critical Care Medicine 2005, 172:631-635.
39. Shahidi N., Fu Y.T., Qian H., Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflammatory Bowel Diseases 2012, 18:2034-2042.
40. ® gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflammatory Bowel Diseases 2011, 17:2340-2349.
41. ® test. Journal of Crohn's Colitis 2012, 6:419-424.
42. ®-TB Gold in-tube assay. Journal of Clinical Microbiology 2010, 48:2672-2676.
43. Diel R., Loddenkemper R., Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest 2012, 142:63-75.
44. Diel R., Loddenkemper R., Niemann S., et al. Negative and positive predictive value of a whole-blood IGRA for developing active TB - an update. American Journal of Respiratory and Critical Care Medicine 2011, 183:88-95.
45. Kik S.V., Franken W.P., Mensen M., et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. European Respiratory Journal 2010, 35:1346-1353.
46. National Tuberculosis Advisory Committee Australia Position statement on interferon-γ release assays in the detection of latent tuberculosis infection. Communicable Diseases Intelligence 2012, 36:125-131.
47. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis and Rheumatism 2006, 54:1075-1086.
48. van Zyl-Smit R.N., Pai M., Peprah K., et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. American Journal of Respiratory and Critical Care Medicine 2009, 180:49-58.
49. Wang L., Turner M.O., Elwood R.K., et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002, 57:804-809.